Cetera Investment Advisers grew its stake in Medline (NASDAQ:MDLN - Free Report) by 128.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,088 shares of the company's stock after buying an additional 29,282 shares during the period. Cetera Investment Advisers' holdings in Medline were worth $2,318,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in MDLN. Sound Income Strategies LLC acquired a new position in shares of Medline in the 4th quarter valued at $25,000. Entrust Financial LLC acquired a new stake in Medline during the 4th quarter worth about $26,000. NBC Securities Inc. acquired a new stake in Medline during the 4th quarter worth about $28,000. Whipplewood Advisors LLC purchased a new stake in Medline during the 1st quarter valued at about $30,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Medline in the fourth quarter valued at about $31,000.
Medline News Summary
Here are the key news stories impacting Medline this week:
- Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
- Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
- Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
- Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
- Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on MDLN. Tigress Financial raised their price objective on Medline from $60.00 to $62.00 and gave the stock a "buy" rating in a research note on Wednesday, May 13th. Deutsche Bank Aktiengesellschaft set a $37.00 target price on Medline in a research report on Thursday. Citigroup reduced their price target on shares of Medline from $60.00 to $55.00 and set a "buy" rating for the company in a research report on Thursday, May 7th. BMO Capital Markets restated an "outperform" rating and set a $47.00 price objective on shares of Medline in a research note on Thursday. Finally, Stifel Nicolaus dropped their price objective on shares of Medline from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $48.50.
Read Our Latest Stock Analysis on MDLN
Insider Transactions at Medline
In other news, major shareholder Private Ltd Gic sold 271,994 shares of Medline stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $35.33, for a total transaction of $9,609,548.02. Following the completion of the transaction, the insider directly owned 24,992,766 shares of the company's stock, valued at $882,994,422.78. The trade was a 1.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jessi L. Corcoran bought 5,000 shares of the business's stock in a transaction dated Friday, June 5th. The shares were purchased at an average cost of $34.15 per share, with a total value of $170,750.00. Following the completion of the acquisition, the insider owned 5,000 shares in the company, valued at approximately $170,750. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold 2,348,612 shares of company stock valued at $83,654,149 in the last 90 days. 0.81% of the stock is currently owned by company insiders.
Medline Stock Up 2.1%
Shares of MDLN opened at $35.23 on Friday. The company has a market capitalization of $46.28 billion and a price-to-earnings ratio of 110.09. Medline has a 52 week low of $32.81 and a 52 week high of $50.88. The stock's 50-day moving average price is $38.22 and its 200-day moving average price is $41.72. The company has a quick ratio of 2.51, a current ratio of 4.33 and a debt-to-equity ratio of 0.66.
Medline (NASDAQ:MDLN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.18. The company had revenue of $7.68 billion for the quarter. On average, sell-side analysts predict that Medline will post 1.49 EPS for the current year.
Medline Company Profile
(
Free Report)
Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
Read More
Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Medline, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medline wasn't on the list.
While Medline currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
